Curated News
By: NewsRamp Editorial Staff
October 10, 2025

Nutriband Partners with Brand Institute for Abuse-Deterrent Fentanyl Patch

Discuss on LinkedIn Discuss on Substack Discuss on Telegram participate in discussion on bluesky View History of this news story on GitHub
Original Source

TLDR

  • Nutriband's AVERSA FENTANYL partnership with Brand Institute positions it to launch the first abuse-deterrent opioid patch, creating a competitive advantage in the pharmaceutical market.
  • Nutriband's subsidiary 4P Therapeutics is working with Brand Institute to develop the global brand identity for AVERSA FENTANYL, which uses transdermal technology to prevent opioid abuse.
  • AVERSA FENTANYL's abuse-deterrent technology helps reduce opioid misuse and accidental exposure, making pain management safer for patients and communities worldwide.
  • Nutriband is developing the world's first abuse-deterrent fentanyl patch using AVERSA technology, partnering with Brand Institute which secured 87% of FDA drug name approvals in 2024.

Impact - Why it Matters

This development represents a crucial advancement in addressing the ongoing opioid crisis that has devastated communities worldwide. The creation of an abuse-deterrent fentanyl patch could significantly reduce prescription opioid misuse, which currently accounts for thousands of overdose deaths annually. For patients requiring strong pain management, this technology offers the therapeutic benefits of fentanyl while incorporating safety features that prevent extraction, injection, or other forms of misuse. Healthcare providers gain a new tool to manage severe pain while minimizing diversion risks, and regulatory agencies see progress in combating the opioid epidemic through technological innovation rather than just restriction. The involvement of former FDA and international regulatory officials in the branding process suggests strong confidence in the product's regulatory pathway and market potential.

Summary

Nutriband Inc. (NASDAQ: NTRB), a pioneering developer of prescription transdermal pharmaceutical products, has announced a significant partnership through its subsidiary 4P Therapeutics with Brand Institute, Inc., the global leader in pharmaceutical brand name and identity development. This collaboration aims to create the worldwide commercial brand name and visual identity for AVERSA FENTANYL, Nutriband's flagship product featuring the revolutionary AVERSA™ abuse-deterrent transdermal technology. The selection of Brand Institute brings formidable expertise to the project, given their impressive track record of securing 75% of global drug name approvals and an astonishing 87% of FDA-approved names in 2024. This strategic alliance positions AVERSA FENTANYL for optimal market recognition and regulatory success as it progresses toward commercialization.

The AVERSA FENTANYL patch represents a groundbreaking advancement in pain management technology, potentially becoming the world's first abuse-deterrent opioid patch. Designed with sophisticated safety features to deter misuse and reduce accidental opioid exposure, this innovative product addresses critical public health concerns surrounding opioid medications. Brand Institute will lead this comprehensive branding initiative in partnership with its regulatory subsidiary, Drug Safety Institute, which boasts an impressive team of former officials from major regulatory bodies including the FDA, EMA, Health Canada, USAN, and WHO. This combined expertise ensures that the branding strategy will not only resonate commercially but also navigate the complex regulatory landscape effectively. For investors and stakeholders seeking additional information, the full press release is available through the InvestorBrandNetwork platform, which provides comprehensive coverage of developments in the biotechnology and life sciences sectors.

Nutriband's corporate mission focuses on developing a diverse portfolio of transdermal pharmaceutical products, with AVERSA FENTANYL serving as their lead development candidate. The company's proprietary AVERSA™ technology represents a versatile platform that can be incorporated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. This technology comes at a crucial time when healthcare systems worldwide are grappling with opioid misuse epidemics. The partnership with Brand Institute, supported by BioMedWire's specialized communications platform within the Dynamic Brand Portfolio, ensures that this important medical advancement receives the professional branding and market positioning it deserves as it moves closer to potentially transforming pain management practices globally.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Nutriband Partners with Brand Institute for Abuse-Deterrent Fentanyl Patch

blockchain registration record for this content.